| To: rkrw who wrote (663) | 9/27/2022 4:56:00 PM | | From: Steve Lokness | | | | Oh my gosh! Look at how bad it is now compared to January;
Message 33681925
Got to be some of these that could merge together and have cash to get through the doldrums I would think. I have been picking up a few just recently - which hasn't proven to be a good decision ...............at least yet. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Steve Lokness who wrote (664) | 9/27/2022 5:14:57 PM | | From: rkrw | | | | Median name was down 50.2% on the year as of that cut, with very few stocks up on the year. Just 6 stocks have doubled vs 25 down 90% or more.
At least one got munched for their cash on hand in TYME. I'm sure they'll be more where that came from. Perhaps some activists will come alive too and try to shut companies down and distribute the remaining cash.
Also seeing some of the lovely companies trading well below cash, raising cash. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: A.J. Mullen | 10/21/2022 11:02:34 AM | | | | | | Immunic (IMUX) dropped 78% today to $2.04, which takes its cap to less than cash on hand according to Yahoo. The drop is due an announcement that an interim look at a Phase 1 trial showed no separation of the treatment arm from placebo at 28 days.
It's one drug, one indication (moderate-severe psoriasis). The same drug is in Phase 1 for Prostate Cancer. Another drug is in three trials: Phase 3 for relapsing MS, Phase 2 for progressive MS and Phase 2 for another disease. Finally, they have a third drug in Phase 1 against Celiac Disease. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: bmaz001 who wrote (627) | 1/6/2023 4:53:17 PM | | From: Area51 | | | | That was a nice list you did last year (although I suspect most people buying from it in January 22 didn't profit much). Are you going to update it this year?
One that I follow is PASG that has been mentioned in this thread before. As of Q3 2022 they had 213 million cash and marketable securities; 46 million in total liabilities; 54 million shares. So (cash - total liabilities) / shares = about 3.30 and now trading 1.88 after closing 2022 at 1.38. (PASG was on your list last year but last January was trading over $6). Do people see better values than that? Always good to diversify because a decent percentage of these will likely run out of cash before they ever generate significant revenue. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: Area51 who wrote (670) | 1/6/2023 5:23:18 PM | | From: Area51 | | | | I looked at 3 I have small positions in: (TL = total Liabilities)
| | (cash-TL)/ shares | price | discount | | FIXX | 2.48 | 1.58 | 36% | | BDTX | 2.69 | 2.06 | 24% | | PASG | 3.28 | 1.88 | 43% | |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: bmaz001 who wrote (672) | 1/11/2023 2:33:55 PM | | From: Area51 | | | | Thanks. Do you (or other thread followers) have some favorites per chance? Something that not only trades below Net current asset value, but also has good prospects for being profitable in the not so distant future?
Failing that if we assume they have no debt (not always true) I guess we can look at (market cap - Enterprise Value)/ market cap and sort on the result and look at the top 10 or 20. Would help if the spreadsheet would let us copy and paste it to an excel spreadsheet, but that ability seems to be disabled? Too many listed for me to do a 100% review I think <g>. |
| | Biotech for less than cash value | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| |
